Two abortion-inducing drugs could soon be reclassified as controlled and dangerous substances in Louisiana under a first-of-its-kind bill that received final legislative passage Thursday and is expected to be signed into law by the governor.

Supporters of the reclassification of mifepristone and misoprostol, commonly known as “abortion pills,” say it would protect expectant mothers from coerced abortions.

Numerous doctors, meanwhile, have said it will make it harder for them to prescribe the medicines that they use for other important reproductive health care needs, and could delay treatment.

Passage of the bill comes as both abortion rights advocates and abortion opponents await a final decision from the U.S. Supreme Court on an effort to restrict access to mifepristone. The justices did not appear ready to limit access to the drug on the day they heard arguments.

The GOP-dominated Legislature’s push to reclassify mifepristone and misoprostol could possibly open the door for other Republican states with abortion bans that are seeking tighter restrictions on the drugs. Louisiana currently has a near-total abortion ban in place, applying both to surgical and medical abortions.

Current Louisiana law already requires a prescription for both drugs and makes it a crime to use them to induce an abortion in most cases. The bill would make it harder to obtain the pills by placing it on the list of Schedule IV drugs under the state’s Uniform Controlled Dangerous Substances Law.

The classification would require doctors to have a specific license to prescribe the drugs, which would be stored in certain facilities that in some cases could end up being located far from rural clinics.

Knowingly possessing the drugs without a valid prescription would carry a punishment including hefty fines and jail time.

More than 200 doctors in the state signed a letter to lawmakers warning that it could produce a “barrier to physicians’ ease of prescribing appropriate treatment” and cause unnecessary fear and confusion among both patients and doctors.

The physicians warn that any delay to obtaining the drugs could lead to worsening outcomes in a state that has one of the highest maternal mortality rates in the country.